Profile: United States trained physician, specializing in internal medicine and infectious diseases with extensive experience conducting clinical trials and a master’s degree from the UK in clinical research.

Personal Information:

• Email:
  • jose@jmresearch.org
• Other names used:
  • Jose Flores
  • Jose F Figueroa

Medical Licenses:

• Florida: ME160805
• Georgia: 96014
• Idaho: M-17171
• Indiana: 01089228A
• Mexico: 3532657 and 4371841
• Missouri: 2023042642
• New Mexico: MD2023-0511
• North Carolina: 2023-00320
• Oklahoma: 40179
• Texas: P1754

Current Appointments:

• July 2023 – current. Preceptor at South University, Nurse Practitioner Program. Savannah, GA.
• August 2021 – current. Preceptor at Indiana University, Master in Health Management. O’Neill School of Public and Environmental Affairs. Indiana University. Bloomington, IN.
• January 2020 – current. Professor at Universidad del Valle de Cuernavaca Medical School. Infectious Diseases, 7th semester at medical school. Cuernavaca, Mexico.
• December 2012 – current. Medical director and primary care provider for Clinica San Felipe; a low-cost primary care medical clinic for Hispanic immigrants in the Houston metro area.
• July 2009 – current. Clinical Researcher, and Internal Medicine and Infectious Diseases physician at JM Research in Cuernavaca, Mexico.

Past Professional Experience:

• March 2018 – November 2022. Physician at Rodriguez Clinical Trials, LLC dba Rodriguez Medical Clinic. Houston, TX.

Rodriguez Medical Clinic is located in the Houston metro area and provides primary care to low-income patients as well as conducts phase II and III clinical trials.

• July 2009 – August 2019. Director at the GeoSentinel Travel Medicine Clinic of Cuernavaca, Mexico. GeoSentinel is a worldwide communication and data collection network for the surveillance of travel related morbidity. It was initiated in 1995 by the International Society of Travel Medicine (ISTM) and the Centers for Disease Control (CDC) as a network of ISTM member travel/tropical medicine clinics.
• July 2009 – September 2011. Consultant for The Center for Infectious Diseases, School of Public Health, The University of Texas Health Science Center in Houston. Houston, Texas.

As an independent contractor for UTSPH my responsibilities include a) clinical and translational research project planning, b) clinical studies design, c) local IRB communications, d) supervision of study and site coordinators, e) supervision of sub-investigators, f) training of UT and BCM rotating medical students, g) the conduction of clinical trials in the field of enteric infectious diseases, and h) logistics and budget managing for the research site in Cuernavaca, Mexico.

• June 2005 – September 2005. Site Coordinator for The University of Texas at Houston managing Travelers’ Diarrhea studies in Cuernavaca, Mexico.
• March 2005 – June 2005. Internal Medicine Hospitalist at Satelite Hospital. Naucalpan, Mexico. The Satelite Hospital is a large private hospital serving the Mexico City metro area.
• March 2005 – June 2005. Internal Medicine attending physician at the North Central Hospital, PEMEX. Mexico City, Mexico.
• September 1999 – August 2000. Program Manager for the HIV/AIDS and Sexual Transmitted Diseases Department at the VIII Health Jurisdiction in the State of Jalisco, Mexico.

Clinical Research Experience: 

Ongoing Projects:

• Principal investigator in a phase I/II/III trial evaluating an mRNA vaccine against Respiratory Syncytial Virus in adults. Study conducted in Cuernavaca, Mexico 2024 – ongoing.
• Principal investigator in a phase 3 Trial evaluating MGL-3196 for the treatment of NASH. Study conducted in Cuernavaca, Mexico 2022 – ongoing. 
• Sub-Investigator in a phase III Trial of Recombinant Coronavirus Vaccine. Study conducted in Cuernavaca, Mexico 2021 – ongoing.

Finished Projects:

• Principal Investigator in a phase 3 trial evaluating Cefepime / Zidebactam for the treatment of Pyelonephritis. Study conducted in Cuernavaca, Mexico 2023 – 2025.
• Principal investigator in a Phase 3 trial evaluating Abrocitinib for the treatment of Atopic Dermatitis. Study conducted in Cuernavaca, Mexico 2023 – 2025.

• Sub/Investigator in a Phase I trial studying Sisunatovir in pediatric patients with RSV infection. Study conducted in Cuernavaca, Mexico 2024 – 2024. Principal investigator in a phase 3 trial evaluating curcumin for Osteorathrosis. Study conducted in Cuernavaca, Mexico 2022 – 2024.
• Sub-investigator in a phase 2/3 study to investigate PF-07321332 (nirmatrelvir) in in pediatric patients with COVID infection. Study conducted in Cuernavaca, Mexico 2022 – 2023.
• Principal investigator in a phase 2/3 Trial evaluating PF07321332 in Patients with COVID-19. Study conducted in Cuernavaca, Mexico 2021 – 2022. 
• Principal investigator in a phase III Trial of Recombinant Coronavirus Vaccine. Study conducted in Cuernavaca, Mexico 2020 – 2022.
• Principal investigator in a phase III study evaluating Arachmol for the treatment of NASH. Study conducted in Cuernavaca, Mexico 2020 – 2021.
• Sub-investigator in a phase III study evaluating Baricitinib in patients with severe atopic dermatitis. Study conducted in Cuernavaca, Mexico 2017 – 2021.
• Sub-Investigator in a phase III study evaluating Risanlizumab for the treatment of Crohn´s disease. Study conducted in Cuernavaca, Mexico 2019 – 2021.
• Sub-Investigator in a phase III study evaluating SHP647 for the treatment of severe Ulcerative Colitis. Study conducted in Cuernavaca, Mexico 2019 – 2021.
• Principal investigator in a phase II study evaluating Cenicriviroc in patients suffering from NASH with hepatic fibrosis. Study conducted in Cuernavaca, Mexico 2017 – 2021.
• Principal investigator in a phase III study evaluating Dapaglifozin in Respiratory Failure in patients with COVID-19. Study conducted in Cuernavaca, Mexico 2020 – 2021.
• Study Coordinator in a phase III study evaluating Relamorelin for the treatment of diabetic gastroparesis. Study conducted in Houston, Texas 2018 – 2020.
• Principal investigator in a phase III study evaluating a quadrivalent influenza vaccine in children. Study conducted in Cuernavaca, Mexico 2018 – 2020.
• Sub-investigator in a phase III study evaluating Pimodivir for the treatment of high-risk patients suffering from Influenza infection. Study conducted in Houston, Texas 2018 – 2020.
• Principal investigator in a phase III study evaluating AAI101 for the treatment of complicated urinary tract infection in hospitalized patients. Study conducted in Cuernavaca, Mexico 2019 – 2020.
• Principal investigator in a phase III study evaluating Pimodivir for the treatment of hospitalized patients suffering from Influenza infection. Study conducted in Cuernavaca, Mexico 2018 – 2019.
• Principal investigator in a phase III study evaluating the combination of L-Carnitine and Atorvastatin for the treatment of dyslipidemia. Study conducted in Cuernavaca, Mexico 2018 – 2019.
• Principal investigator in a phase II study evaluating GSK3772847 in patients suffering from moderately severe asthma. Study conducted in Cuernavaca, Mexico 2018 – 2019.
• Sub-investigator in a phase II/III study evaluating ABP798 versus Rituximab in patients suffering from Non-Hodking Lymphoma. Study conducted in Cuernavaca, Mexico 2017 – 2019.
• Principal investigator in a phase IV study evaluating a combination of bicarbonate and omeprazole in patients with GERD. Study conducted in Cuernavaca, Mexico 2017 – 2019.
• Principal Investigator in a phase III study evaluating RJ-0265 for the treatment of onychomycosis in Adults. Study conducted in Cuernavaca, Mexico 2018 – 2019.
• Principal investigator in a phase II study evaluating ALS-8176 for the treatment of Syncytial Respiratory virus in Adult patients. Study conducted in Cuernavaca, Mexico 2018 – December 2018.
• Sub-Investigator in a phase III multicenter study evaluating ODM-201 in patients with metastatic prostate cancer. Study conducted in Cuernavaca, Mexico 2017 – 2018.
• Sub-Investigator in a phase IV multicenter study evaluating Sofosbuvir-based regimens in patients with Chronic Hepatitis C Virus Infection. Study conducted in Cuernavaca, Mexico 2016 – 2018.
• Principal investigator in a phase IIb multicenter clinical trial evaluating Arachmol in patients suffering from NASH. Study conducted in Cuernavaca, Mexico 2016 – 2018.
• Sub-investigator in a phase III multicenter clinical trial evaluating a vaccine against C. difficile. Study conducted in Cuernavaca, Mexico 2015 – 2017.
• Sub-Investigator in a phase IV multicenter clinical trial evaluating Lecardinipine with or without thiazide in patients suffering from arterial hypertension. Study conducted in Cuernavaca, Mexico 2016 – 2017.
• Sub-Investigator in a phase IV multicenter study evaluating Dengvaxia vaccine to prevent dengue virus infection. Study conducted in Cuernavaca, Mexico 2016 – 2018.
• Sub-Investigator in a study evaluating a diagnostic test for Zika virus infection. Study conducted in Houston, Texas 2017 – 2017.
• Principal investigator in a phase III multicenter study evaluating Rifaximin to treat patients with Traveler´s Diarrhea. Study conducted in Cuernavaca, Mexico 2016 – 2017.
• Sub-investigator in a phase III multicenter clinical trial evaluating Mupirocin in patients suffering from Impetigo. Study conducted in Cuernavaca, Mexico 2016.
• Principal Investigator in a phase III multicenter study evaluating CEM-102 in patients suffering Acute Bacterial Skin and Skin Structure Infections. Study conducted in Houston, TX USA 2016.
• Sub-investigator in a phase III multicenter clinical trial evaluating Dolutegravir in patients suffering from HIV infection and active tuberculosis. Study conducted in Cuernavaca, Mexico 2015 – 2016.
• Principal investigator in a phase III multicenter clinical trial evaluating Aclidinium Bromide on Long- Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD. Study conducted in Houston, TX, USA 2013 – 2016.
• Principal Investigator in a phase III muticenter clinical trial evauating Atrasentan in patients suffering from diabetic nephropathy. Study conducted in Houston, TX USA 2015 – 2016.
• Sub-investigator in a phase III multicenter clinical trial evaluating Rifaximin in patients suffering from Travelers’ Diarrhea. Study conducted in Cuernavaca and Guadalajara, Mexico 2015 – 2015.
• Principal investigator in a phase III multicenter clinical trial evaluating IV Solithromycin to treat patients suffering from community acquired pneumonia. Study conducted in Houston, TX, USA 2014- 2015.
• Principal investigator in a phase III multicenter study evaluating a medical device to diagnose Helicobacter pylori infection. Study conducted in Houston, TX, USA 2014-2015.
• Principal investigator in a phase III multicenter clinical trial evaluating Favipiravir to treat patients with Influenza infection. Study conducted in Cuernavaca, Mexico. 2014-2015.
• Principal investigator in a phase III multicenter clinical trial evaluating Delafloxacin to treat patients with gonorrhea. Study conducted in Houston, TX, USA 2014-2014.
• Principal investigator in a phase III multicenter clinical trial evaluating PO Solithromycin to treat patients suffering from community acquired pneumonia. Study conducted in Houston, TX, USA 2013- 2014.
• Principal investigator in a phase III multicenter clinical trial evaluating a vaginally administered antibiotic to treat patients with bacterial vaginosis. Study conducted in Houston, TX, USA 2014-2014.
• Principal investigator in a phase III multicenter clinical trial evaluating Rifaximin to treat patients with diarrhea-predominant IBS. Study conducted in Houston, TX, USA 2013-2014.
• Principal investigator in a phase IV national multicenter clinical trial evaluating a muscle relaxant and NSAIDs for muscle and joint pain. Study conducted in Cuernavaca, Mexico 2012-2013.
• Principal investigator in a phase III international multicenter clinical trial using Rifamycin to treat patients with travelers’ diarrhea. Study conducted in Cuernavaca, Mexico 2010-2012.
• Sub-investigator in a phase III international multicenter clinical trial using an E. coli vaccine to prevent travelers’ diarrhea. Study conducted in Cuernavaca, Mexico 2009-2010.
• Principal investigator in a phase IV national multicenter clinical trial to treat pharyngitis. MPIMU. Study conducted in Cuernavaca, Mexico 2009.
• Principal investigator in a phase IV national multicenter clinical trial to treat bronchitis. MIMU. Study conducted in Cuernavaca, Mexico 2009.
• Principal investigator in a phase III multicenter clinical trial using Rifaximin to prevent the occurrence of travelers’ diarrhea. Study conducted in Cuernavaca, Mexico 2009-2010.
• Sub-investigator in a phase III multicenter clinical trial using Prulifloxacin to treat patients with travelers’ diarrhea. Study conducted in Cuernavaca, Mexico 2007-2008.
• Sub-investigator in a phase II multicenter clinical trial using an E. coli vaccine to prevent travelers’ diarrhea. Study conducted in Cuernavaca, Mexico 2006-2007.
• Principal investigator for Mexico in a phase III multicenter clinical trial using Prulifloxacin to treat patients with travelers’ diarrhea. Study conducted in Guadalajara and Cuernavaca, Mexico 2006- 2007.
• Sub-investigator in a phase III international multicenter clinical trial using Rifaximin with and without Loperamide to treat patients with travelers’ diarrhea. Study conducted in Cuernavaca, Mexico 2004-2005.
• Sub-investigator in a phase III international multicenter clinical trial using Clexane to prevent deep venous thrombosis in hospitalized patients. Study conducted in Mexico City 2002-2003.
• Sub-investigator and Research Coordinator in a phase III international multicenter clinical trial using Raptiva to treat patients with moderate to severe psoriasis. Study conducted in Mexico City 2002- 2003.

Education:

• Master in Business Administration. February 2015 – February 2017:

Kelley School of Business.

Indiana University, Bloomington, USA.

• Master in Science. February 2012 – November 2014:

University of Liverpool, UK.

Master Degree in Clinical Research. 

• Clinical Fellowship. July 2007 – June 2009:

Infectious Diseases.

University of Texas Health Science Center at Houston, Texas, USA.

• Research Fellowship. November 2005 – June 2007:

Enteric Infectious Diseases

University of Texas Health Science Center at Houston, Texas, USA.

• Residency March. 2001 – February 2005:

Internal Medicine

PEMEX North Central Hospital

National Autonomous University of Mexico, Mexico City, Mexico.

• Medical School. September 1994 – August 2000:

Physician Surgeon and Obstetrician. University of Guadalajara.

Guadalajara, Mexico.

Educational Commission for Foreign Medical Graduates: 0-663-056-0.

Honors and Awards:

• 2017. National Investigator Level 1 “Investigador Nacional Nivel 1” 2015-2021, CONACyT,
• 2015. Fellow of the Infectious Diseases Society of America, USA.
• 2012. Fellow of the American College of Physicians, Philadelphia, USA.
• 2010. Honor Award Certificate, National Center for Emerging and Zoonotic Infectious Diseases. For the development of a worldwide network of tropical/travel medicine clinics that has excelled in detecting and communicating trends in travel-related morbidity. NCEZID Recognition Awards Ceremony. USA.
• 2009. Infectious Diseases Society of America Travel Grant, 47th IDSA Annual Meeting. USA.
• 2009. Special Citation for Fellows-in-Training, 47th IDSA Annual Meeting. USA.
• 2008. Wyeth ID Fellows ICAAC/IDSA Program Grant, 48th Annual ICAAC, 46th IDSA Annual Meeting. USA.
• 2007. Infectious Diseases Society of America Travel Grant, 45th IDSA Annual Meeting. USA.
• 2005. George McCracken ID Fellows Travel Grant, American Society for Microbiology, 45th Annual ICAAC. USA.

Papers in Peer Reviewed Journals:

• Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021; 27(10): 1825-35.
• Flores-Figueroa J, Paredes-Paredes M, Badillo I, Botello G, Pacheco U and McGovern S. Remuneration in the United States and Mexico: Assessing the Level of Influence on Potential Clinical Research Participants about their decision to Participate in a Clinical Trial and the Risk for Fraud. Clin Ethics 2018; 13: 98-105.
• Flores Figueroa J, Morales Cerda JD, Belalcazar Lopez VM, Zuqui Ramirez MA. [Efficacy and safety of 50mg tolperisone and 300mg paracetamol. Clinical trial in phase IV] [Article in Spanish]. Rev Latinoam Cir Ortop 2017; 2: 2.

• Flores-Figueroa J, Ortiz-Navarrete V, Paredes-Paredes M, Espinosa-Lopez FR and Castro-D´Franchis LJ. Urinary IL-8 as an Early Diagnostic Tool for Nosocomial Urinary Tract Infection. Med Sci Tech 2017; 58: 15-20.
• Stevens, Esposito, Stoney, Hamer, Flores-Figueroa, Bottieau, Connor, Gkrania-Klotsas, Goorhuis, Hynes, Libman, Lopez-Velez, McCarthy, Sonnenburg, Schwartz, van Genderen, Benson and Leung. Clostridium difficile-associated diarrhea in returning travelers. J Trav Med 2017; 1-6.
• Barrera C, Mykietiuk A, Metev H, Floarea Nitu M, Karimjee N, Doreski A, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg DJ, Rowe BH, Flores-Figueroa J, Sokolowska B, Clark K, Keedy K, Sheets A, Scott D, Das A, Jamieson B, Fernandes P and Oldach D. SOLITAIRE-ORAL: A Randomized, Double-Blind, Multi-Center, Global Phase 3 Study Comparing the Efficacy and Safety of Oral Solithromycin to Oral Moxifloxacin for Treatment of Community Acquired Bacterial Pneumonia (CABP). Lancet Infect Dis 2016; 16: 421-30.
• DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED and Totoritis MC. Targeting of Rifamycin SC to the Colon for Treatment of Travelers’ Diarrhoea: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. J Trav Med 2014; 21: 369-76.
• Nair P, Okhuysen P, Jiang Z, Carlin L, Belkind-Gerson J, Flores J, Paredes-Paredes M and DuPont H. Persistent Abdominal Symptoms in U.S. Adults After Short-term Stay in Mexico. J Trav Med 2014; 21: 153-8.
• Paredes-Paredes M, Flores-Figueroa J and DuPont HL. Advances in the Treatment of Travelers’ Diarrhea. Curr Gastroenterol Rep 2011; 13: 402-7.
• Flores J, DuPont HL, Jiang ZD, Okhuysen PC, Melendez-Romero JH, Gonzalez-Estrada A, Carrillo I and Paredes M. A Randomized, Double-Blind, Study of Rifaximin 550mg vs. Placebo in the Prevention of Travelers’ Diarrhea in Mexico during the Dry Seasons. J Travel Med 2011; 18:333-6.
• Flores-Figueroa J, Okhuysen PC, von Sonnenburg F, DuPont HL, Libman MD, Keystone JS, Hale DC, Burchard G, Han PV, Wilder-Smith A, Freedman DO for the GeoSentinel Survbeillance Network. Patterns of Illness in Travelers Visiting Mexico and Central America: The GeoSentinel Experience. Clin Infect Dis 2011; 53: 523-31.
• Mohamed JA, DuPont HL, Flores J, Palur H, Nair P, Jiang ZD, Guo D, Belkind-Gerson J and Okhuysen PC. Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with and increased risk for bacterial diarrhea in North American travelers to Mexico. Clin Infect Dis 2011; 52: 1332-41.
• Villa N, Okhuysen P, Flores-Figueroa J, Paredes M, Jiang ZD, Belkind-Gerson J, Mohamed J, Nair P, Carlin L and DuPont H. Campylobacter jejuni is Not an Important Pathogen as a Cause of Travelers’ Diarrhea in U.S. Travelers to Mexico. J Travel Med 2011; 18: 56-8.
• Paredes-Paredes M, Okhuysen PC, Flores J, Mohamed JA, Padda RS, Gonzalez-Estrada A, Haley CA, Carlin LG, Nair P and DuPont HL. Seasonality of Diarrheagenic Eschericha coli pathotypes in U.S. Students Acquiring Diarrhea in Mexico. J Travel Med 2011; 18: 121-5.
• Ajami NJ, Koo HL, Darkoh C, Atmar RL, Okhuysen PC, Jiang ZD, Flores J and DuPont HL. Characterization of Norovirus-associated Travelers’ Diarrhea. Clin Infect Dis 2010; 51: 123-30.
• Ouyang-Latimer J, Ajami NJ, Jiang ZD, Okhuysen PC, Paredes M, Flores J and Dupont HL. Biochemical and Genetic Diversity of Enterotoxigenic Escherichia coli Associated with Diarrhea in United States Students in Cuernavaca and Guadalajara, Mexico, 2004-2007. J Infect Dis 2010; 201: 1831-8.
• Flores J, DuPont HL, Paredes-Paredes M, Aguirre-Garcia MM, Rojas A, Gonzalez A and Okhuysen PC. Whole Blood Interferon Gamma (IFN-γ) Response to Cholera Toxin B Subunit and Resistance to Travelers’ Diarrhea. A Pilot Study of Cellular Immune Response in Enterotoxigenic Escherichia coli Associated Diarrhea. Clin Vac Imm 2010; 17: 879-81.
• Flores J and Okhuysen PC. Genetics of Susceptibility to Infection with Enteric Pathogens. Curr Opin Infect Dis 2009; 22: 471-6.
• Mohamed JA, Dupont HL, Jiang ZD, Flores J, Carlin LG, Belkind-Gerson J, Martinez-Sandoval FG, Guo D, White Jr AC and Okhuysen PC. A Single-Nucleotide Polymorphism in the Gene Encoding Osteoprotegerin, an Anti-inflammatory Protein Produced in Response to Infection with Diarrheagenic Escherichia coli, Is Associated with an Increased Risk of Nonsecretory Bacterial Diarrhea in North American Travelers to Mexico. J Infect Dis 2009; 199: 477-85.
• Flores J and Okhuysen PC. Enteroaggregative Escherichia coli Infection. Curr Opin Gastroenterol 2009; 25: 8-11.
• Nair P, Mohamed JA, DuPont HL, Figueroa JF, Carlin LG, Jiang ZD, Belkind-Gerson J, Martinez- Sandoval FG and Okhuysen PC. Epidemiology of Cryptosporidiosis in North American travelers to Mexico. Am J Trop Med Hyg 2008; 72: 210-4.
• Flores J, DuPont HL, Lee SA, Belkind-Gerson J, Paredes M, Mohamed JA, Armitige LY, Guo DC and Okhuysen PC. Influence of Host Interleukin-10 Polymorphisms on Development of Traveler’s Diarrhea Due to Heat-Labile Enterotoxin-Producing Escherichia coli in Travelers from the United States Who Are Visiting Mexico. Clin Vac Imm 2008; 15: 1194-8.
• Grimes KA, Mohamed JA, DuPont HL, Padda RS, Jiang ZD, Flores J, Belkind-Gerson J, Martinez- Sandoval FG and Okhuysen PC. A PCR Based Assay for the Detection of Diarrheagenic Escherichia coli from Occult Blood Detection Cards in U.S. Travelers to Mexico with Acute Diarrhea. J Clin Microbiol 2008; 46: 2227-30.
• Frech SA, DuPont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Melendez-Romero JHM, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA and Glenn GM. Protection against Travelers’ Diarrhea in a Randomized, Double-blind, Placebo- Controlled Field Trial of a Patch Containing Heat-Labile Toxin from Escherichia coli. Lancet 2008; 371:2019-2025.
• Flores J, DuPont HL, Jiang ZD, Belkind-Gerson J, Mohamed JA, Carlin LG, Padda RS, Paredes M, Martinez-Sandoval JF, Villa NA and Okhuysen PC. Enterotoxigenic Escherichia coli Heat-Labile Toxin Seroconversion in US travelers to Mexico. J Travel Med 2008; 3: 156-61.
• Huang DB, Brown EL, DuPont HL, Cerf J, Carlin L, Flores J, Belkind-Gerson J, Nataro JP and Okhuysen PC. Seroprevalence to the enteroaggregative Escherichia coli virulence factor dispersin among USA travelers to Cuernavaca, Mexico: A Pilot Study. J Med Microbiol. 2008; 57: 476-9.
• Mohamed JA, DuPont HL, Jiang ZD, Belkind-Gerson J, Figueroa JF, Armitige LY, Tsai A, Nair P, Martinez-Sandoval FJ, Guo D, Hayes P and Okhuysen PC. A Novel Single Nucleotide Polymorphism in the Lactoferrin Gene Is Associated with Susceptibility to Diarrhea in North American Travelers to Mexico. Clin Infect Dis 2007; 44: 945-52.
• Castro DFLJ, Espinosa LFG and Flores FJ. [Digestive Bleeding due to Peptic Ulcer Disease Treatment: Omeprazol vs Ranitidine] [Article in Spanish]. Rev Asoc Med Crit Ter Int 2006; 20: 87-92.
• Ramirez HJM and Figueroa JF. [Bispectral monitorization at the Critical Care Unit: clinical application and actual evidences] [Article in Spanish]. Rev Asoc Mex Med Crit Ter Int 2004; 18: 192-8.

Book Chapters:

• Palermo M, Flores-Figueroa J and Paredes-Paredes M: Therapeutics and Vaccines against pathogenic Escherichia coli. In: Torres AG, ed. Pathogenic Escherichia coli in Latino America. Springer, ISBN 978-3-319-45092-6. 2016: Chapter 11.
• Flores-Figueroa J and Paredes-Paredes M: [Cephalosporins] [Chapter in spanish]. In: Espinosa- Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Grupo M y M, ISBN 967-607- 95532-9-0. 2012: 511-21.
• Paredes-Paredes M and Flores-Figueroa J: [New antimicrobial agents] [Chapter in spanish]. In: Espinosa-Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Grupo M y M, ISBN 967- 607-95532-9-0. 2012: 367-74.
• Flores-Figueroa J and Okhuysen PC: Cryptosporidiosis. In: DecisionSupportInMedicine.com: Program – Pediatrics (CDS:PEDS). 2011.
• Flores J and Okhuysen PC: Enteroaggregative E. Coli. In: Alfredo G. Torres, ed. Pathogenic Escherichia coli in Latin America. USA: Bentham Books, eISBN: 978-1-60805-192. 2010: Chapter 4. http://www.bentham.org/ebooks/9781608051922/index.htm.
• Flores J and Okhuysen PC: Enterotoxigenic E. Coli. In: Alfredo G. Torres, ed. Pathogenic Escherichia coli in Latin America. USA: Bentham Books, eISBN: 978-1-60805-192. 2010: Chapter 6. http://www.bentham.org/ebooks/9781608051922/index.htm.
• Flores-Figueroa J and Paredes-Paredes M: [Bioterrorism, Clinical evaluation and therapeutic management] [Chapter in spanish]. In: Espinosa-Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Grupo M y M, ISBN 968-5157-08-0. 2008: 269-78.
• Paredes-Paredes M and Flores-Figueroa J: [New antimicrobial agents] [Chapter in spanish]. In: Espinosa-Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Grupo M y M, ISBN 968- 5157-08-0. 2008: 279-88.
• Flores-Figueroa J and Paredes-Paredes M: [Cephalosporins] [Chapter in spanish]. In: Espinosa-Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Grupo M y M, ISBN 968-5157-08- 0. 2008: 429-40.
• Espinosa-Lopez FR and Flores-Figueroa J: [Antimicrobials for Nosocomial Infections] [Chapter in spanish]. In: Espinosa-Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Medicina y Mercadotecnia, ISBN 968-7827-54-8. 2003: 169-80.
• Espinosa-Lopez FR and Flores-Figueroa J: [New Anti-infectious drugs] [Chapter in spanish]. In: Espinosa-Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Medicina y Mercadotecnia, ISBN 968-7827-54-8. 2003: 181-93.
• Espinosa-Lopez FR and Flores-Figueroa J: [Cephalosporins] [Chapter in spanish]. In: Espinosa- Lopez FR, ed. Terapeutica en Enfermedades Infecciosas. Mexico: Medicina y Mercadotecnia, ISBN 968-7827-54-8. 2003: 299-310.

Associations:

• Internal Medicine College of Mexico, CMIM. 2005 – Current.
• American Society for Microbiology. 2005 – Current. (55923569)
• Fellow of American College of Physicians. 2005 – Current. (01312462)
• Infectious Diseases Society of Houston. 2007 – Current.
• Infectious Diseases Society of America. 2007 – Current. (00022155)
• International Society for Infectious Diseases. 2008 – Current. (00052305)
• International Society for Travel Medicine. 2012 – Current (10760)
• Latin American Coalition for E. coli Research (LACER). 2009 – Current.
• Collaborative Member of the National School of Tropical Medicine, USA. 2012 – Current.

Other Educational / Mentoring Experience:

• American Society for Microbiology, Minority Mentoring Program. Since 2007.
• Reviewer for Emerging Infectious Diseases, CDC. During 2009.
• Reviewer for International Journal of Immunology. 2012-2015 (101613)
• Reviewer for Clinical Medicine Reviews in Therapeutics. 2012-2015
• Reviewer for Journal of Travel Medicine. 2012-2015
• Reviewer for Journal of Pharmacy and Pharmacology Research. Since 2013-2016
• Vice-chair for Migrant Health Committee, International Society for Travel Medicine. 2013-2014
• Editorial Board Member at the International Journal of Genetics and Genomics. 2014-2016

• Member of the Research and Awards Committee, International Society for Travel Medicine. 2018-2024